JUL 28, 2026 · JOURNAL ARTICLE
Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study
The Lancet
Phase 3 RCT demonstrates ralinepag significantly reduces clinical worsening in PAH (HR 0.45, p<0.0001) versus placebo in 687 patients with contemporary background therapy, with acceptable safety profile supporting clinical use.
Reported
Primary endpoint (first clinical…64 of 350 (18%)
Primary endpoint (first clinical…121 of 337 (36%)
Hazard ratio for clinical worseni…0.45